Feed aggregator

BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree

Biospace news - Fri, 04/26/2024 - 02:00
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree 4/26/2024

Tessera Cuts Dozens of Jobs Following Positive Preclinical Results

Biospace news - Fri, 04/26/2024 - 02:00
Tessera Cuts Dozens of Jobs Following Positive Preclinical Results 4/26/2024

AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure

World Pharma News - Thu, 04/25/2024 - 10:00
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the AB-1002 program. AB-1002 is an investigational one-time gene therapy that is administered to the heart with the intention of helping to promote the production of a constitutively active form of protein inhibitor 1 (I-1c) designed to block the action of protein phosphatase 1.

BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1

Biospace news - Thu, 04/25/2024 - 02:00
BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1 4/25/2024

Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20%

Biospace news - Thu, 04/25/2024 - 02:00
Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20% 4/25/2024

Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy

Biospace news - Thu, 04/25/2024 - 02:00
Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy 4/25/2024

Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery

Biospace news - Thu, 04/25/2024 - 02:00
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery 4/25/2024

Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1

Biospace news - Thu, 04/25/2024 - 02:00
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1 4/25/2024

FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier

Biospace news - Thu, 04/25/2024 - 02:00
FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier 4/25/2024

FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women

Biospace news - Thu, 04/25/2024 - 02:00
FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women 4/25/2024

7 Types of Difficult Bosses and How to Deal With Them

Biospace news - Thu, 04/25/2024 - 02:00
7 Types of Difficult Bosses and How to Deal With Them 4/25/2024

Why Biopharma Companies Avoid Hiring People Who Need Visas

Biospace news - Thu, 04/25/2024 - 02:00
Why Biopharma Companies Avoid Hiring People Who Need Visas 4/25/2024

Where Do We Go From Here? The Future of Women's Health

Biospace news - Thu, 04/25/2024 - 02:00
Where Do We Go From Here? The Future of Women's Health 4/25/2024

Researchers publish final results of key clinical trial for gene therapy for sickle cell disease

World Pharma News - Wed, 04/24/2024 - 10:00
In a landmark study, an international consortium led by researchers at Children's Hospital of Philadelphia (CHOP) published the final results of a key clinical trial of the gene therapy CASGEVY (exagamglogene autotemcel) for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). The study found that 96.7% of patients in the study did not have any vaso-occlusive crises (VOCs) - a blockage that results in lack of oxygen and painful episodes - for at least one year, and 100% were able to remain hospitalization-free for the same length of time.

Optimal timing maximises Paxlovid benefits for treating COVID-19

World Pharma News - Tue, 04/23/2024 - 10:00
Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.

The findings suggest that taking Paxlovid three to five days after COVID-19 symptoms emerge may maximise the drug's ability to reduce viral loads, minimise viral spread and reduce viral rebound.

Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales

Biospace news - Tue, 04/23/2024 - 02:00
Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales 4/23/2024

Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win

Biospace news - Tue, 04/23/2024 - 02:00
Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win 4/23/2024

Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates

Biospace news - Tue, 04/23/2024 - 02:00
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates 4/23/2024

ImmunityBio Wins FDA Approval for First IL-15 Superagonist for NMIBC

Biospace news - Tue, 04/23/2024 - 02:00
ImmunityBio Wins FDA Approval for First IL-15 Superagonist for NMIBC 4/23/2024

FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data

Biospace news - Tue, 04/23/2024 - 02:00
FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data 4/23/2024